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 The nucleus is the brain of the cell and is the site of regulation of processes such as 
DNA replication, transcription and cell cycle. Given its importance in cell function, 
several known bacterial proteins have been shown to modulate nuclear processes to co-
opt the host cell for the benefit of the bacteria. Such proteins, termed nucleomodulins, 
can modulate either nuclear DNA or proteins through a variety of mechanisms. Coxiella 
burnetii is a Gram negative, obligate intracellular pathogen and the etiological agent of 
the zoonotic disease known as Q fever. The goal of this project is to determine if C. 
burnetii employs any of its type IVB secretion system (T4SS) substrates to act as 
nucleomodulins. In a large-scale screen of T4BSS substrates, we showed six substrates 
that exhibited nuclear localization when expressed ectopically in HeLa cells. 
Bioinformatic analysis revealed that two of these potential Nucleomodulins, CBU0388 
and CBU0794, contained potential nuclear localization signals (NLS). We tested the 
functionality of these regions by making specific amino acid deletions and comparing 
the impact on their nuclear localization patterns. To predict functionality of these 
substrates, we conducted an Epistasis Miniarray profile (EMAP) screen in S. cerevisiae 
which provided a global quantitative genetic profile of host interactions. Our results 
support our hypothesis these two previously uncharacterized C. burnetii substrates act 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Coxiella burnetii Disease and Intracellular lifecycle 
C. burnetii is an obligate intracellular pathogen and the etiological agent of Q 
fever, a zoonotic disease spread through aerosoliziation of contaminated animal products 
[1]. This disease is readily transmitted with a low infectious dose by aerosol and has 
potential to be a bioterrorist weapon, so thus has been classified as a category B select 
agent [2]. After transmission of aerosolized particles, the organism displays specificity 
for infecting primary alveolar macrophages.  
The natural hosts for C. burnetii include cows, sheep, and goats, with human 
infection being a result of exposure to contaminated animal products. This makes C. 
burnetii infections endemic to farming communities. The most recent notable outbreak 
occurred between 2007 and 2009 in the Netherlands and resulted in 3,523 cases of 
disease [3]. The resulting disease, termed Q fever, from its original name of Query fever 
was defined when the causative agent was discovered in the 1930s [4]. Symptoms of Q 
fever include a flu-like illness with high cyclic fever, although infection often can be 
asymptomatic. The treatment of choice of C. burnetii infection is doxycycline, which has 
been very effective against acute Q fever. In rare cases, Q fever can become chronic and 
have localized complications such as endocarditis, hepatitis, or myocarditis [5].  
Q-Vax, a whole-cell vaccine available in Australia has been shown to be 
effective at preventing C. burnetii infection. Unfortunately, this vaccine elicits an 
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adverse response in individuals with prior exposure to the bacterium [6]. Current 
research by our lab, and others, is ongoing to identify a vaccine that is protective and 
does not have these adverse responses. 
The virulent Phase I organisms possesses smooth lipopolysaccharide (LPS) that, 
upon serial passage, undergoes a phase variation to an avirulent Phase II, with rough 
LPS [7]. This phase variation is due to a truncated O antigen on Phase II which lacks 
terminal sugars [8]. Since this is the only difference between virulent Phase I and 
avirulent Phase II, the full-length LPS is thought to be essential for virulence [9]. Phase 
II is approved to be handled in Biosafety Level 2 conditions (BSL2), while Phase I is 
restricted in a Biosafety Level 3 and Select Agent registered laboratory. Phase I and 
Phase II C. burnetii behave similarly during infection, so Phase II is commonly used for 
research [10]. Phase I and Phase II act similarly in replication kinetics and have an 
indistinguishable lifecycle in a Coxiella-containing vacuole (CCV), so most cellular 
mechanisms are studied in Phase II [10]. 
C. burnetii survives in the environment due to its ability to switch between two 
morphological forms that can be sectored into developmental stages. In the first stage, 
the small cell variant (SCV) is metabolically inactive and resistant to environmental 
changes. The SCV is also the infectious form, which upon entry into the host cells 
switches to the large cell variant (LCV) [11]. The LCV is the larger replicative form, 
which is only found inside cells. Because of this environmental stability, transmission of 
C. burnetii has also been shown to be transmitted through human or blood contact [12].  
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Upon aerosolization, C. burnetii enters the cell through a passive process that 
requires actin-dependent phagocytosis [13]. Virulent Phase I C. burnetii binds to 
phagocytes by using αVβ3 as its main endocytosis receptor, which results in RAC1-
dependent phagocytosis; the C. burnetii ligand for binding the receptor is still unknown 
[14]. Despite its trophism for alveolar macrophages, C. burnetii is capable of infecting 
many cell types. Although the receptor of non-phagocytic cells is unknown, entry 
requires cytoskeletal rearrangement [15]. Following uptake by the cell, C. burnetii 
utilizes the endocytic pathway to set up its replicative niche , the CCV [16]. 
The CCV is a unique replicative niche compared to most other intracellular 
organisms. C. burnetii makes its home in what is typically considered to be a terminal 
phagolysosome which contains typical markers that stain this organelle such as Lamp1 
and Rab7 [17] . The full list of proteins associated with the CCV is not known, 
unfortunately, so there is a lack of understanding of all the requirements for C. burnetii 
growth in its replicative niche. Fusion of the autophagosome with lysosomes causes 
acidification of vacuole contents to a pH of about 4.5, too acidic for most bacteria to 
survive. This acid adaptation is a requirement for C. burnetii replication to occur inside 
the vacuole [18]. This vacuole fusion and acidification is not unique to only C. burnetii. 
Interestingly, C. burnetii can share a vacuole with Mycobacterium tuberculosis and 
Mycobacterium avium [19], Trypanosoma cruzi [20, 21], Leishmania amazonensis [22], 






The genome of C. burnetii encodes a Sec-dependent secretion system, as well as 
a type Ia, type II, a type IV pilus and a type IV secretion system [24]. The C. burnetii 
type IV secretion system is homologous to the Dot/Icm system (defect in organelle 
trafficking/intracellular multiplication) of Legionella pneumophila, (encoding 23 of the 
26 genes from L. pneumophila) [25]. The functional homology was further supported n 
by the ability of L. pneumophila to cross-complement mutants of C. burnetii in structural 
components of the Dot/Icm system [26, 27]. C. burnetii uses the Dot/Icm system to 
secrete and deliver a number of effector proteins into the host cytosol for modulation of 
the host cell. The Dot/Icm secretion system in C. burnetii is required for important 
cellular functions including intracellular replication and vacuole formation, as both of 
these processes are defective in any Dot/Icm mutant [28]. Because of the similarity 
between their Dot/Icm secretion systems, L. pneumophila has been used as a surrogate 
host in multiple screens to test predicted candidates for secretion [29-31]. To date, 
secretion studies as well as bioinformatic screens have identified over 100 Dot/Icm 
substrates [30-33] encoded by the Nine Mile strain. 
Animal Models 
 Animal models of Q fever have been elusive since Phase II C. burnetii has 
limited virulence in an immunocompetent host animal. To circumvent this problem, our 
lab developed a mouse model using SCID mice, which lack functional B and T cells to 
provide a model of human infections of immunocompromised hosts with this strain [34]. 
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This mouse model shows bacterial replication, massive splenomegaly and dissemination 
to multiple tissues including the spleen, lungs and heart. The SCID mouse model has 
provided a unique tool to study Himar1 transposon mutants and their potential 
contribution to virulence.  
In addition to the SCID mouse model, a moth model using Gallaria mellonella 
has also recently been developed [35]. This model provides a tool for studying potential 
virulence determinants in C. burnetii. This model is economical and especially good for 
high-throughput analyses. The major limitation to this model is that Gallaria cannot 
fully mimic the mammalian host response because it lacks specific components, 
including NOD-like receptors (NLRs) [36]. 
Genetic Tools 
Genetic manipulation in C. burnetii is a relatively recent advancement. The 
genome was sequenced in 2003, a little over a decade ago [24]. Since then, experimental 
advances have enabled limited genetic manipulation of the bacteria. A successful 
transformation of an exogenous plasmid into C. burnetii was first reported nearly fifteen 
years ago [37]. Despite this, it wasn’t until more recent years that introduction of a 
plasmid genetic system could allow us to create a targeted gene mutation [38].  
An axenic (cell-free) media system, Acidified Citrate Cysteine Medium (ACCM-
2) permits growth of C. burnetii outside of tissue culture cells [39, 40]. This medium 
uses an acidic pH and microaerophillic conditions to replicate the naturally intracellular 
environment for C. burnetii growth. This media can also be used to make agar plates, so 
individual clones of C. burnetii on plates can be isolated. Since the initial ACCM-2 
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formula, improvements have been made to allow arginine selection, based on C. burnetii 
auxotrophy for the amino acid Arginine [41]. Development of ACCM-2 has now 
allowed gene inactivation in C. burnetii to be possible. Our lab and others have 
developed a mariner-based Himar1 transposon system to generate a random library of 
mutants, a technique we are continuing to optimize for creation of an expanding library.  
Current state of effector research 
Despite recent genetic advances in C. burnetii, there still remains a huge gap in 
understanding of the functions of most T4SS effectors. To date, only a handful of T4SS 
effectors have been characterized and a number of screens have been done to identify 
effectors and their potential function [30, 31, 42]. These screens identified potential 
effectors based on homology to Dot/Icm substrates of L. pneumophila, PmrA regulation 
sites, presence of eukaryotic-like motifs and secretion in a CyA or BlaM assay. 
Collectively these screens identified greater than 100 Dot/Icm effectors in C. burnetii, 
but few have been fully characterized.   
Two of the best-characterized C. burnetii effectors are Cig2 (also called CvpB) 
and Cig57. Both of these effectors were identified through a screen of transposon 
mutants looking to identify mutants that were required for CCV biogenesis [43]. 
Interestingly, the mutants identified in this screen displayed unique phenotypes in 
regards to vacuole formation. Mutants in Cig57 showed decreased replication despite the 
ability to form a spacious vacuole. Also unique to previously identified phenotypes, 
mutants in Cig2 displayed a multi-vacuolar phenotype suggesting that they lack the 
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ability to fuse their CCVs, resulting in multiple small vacuoles.  
Since their initial identification, Cig57 has been shown to interact directly with 
the clathrin-associated protein FCHO2 [44]. This interaction was dependent on an 
endocytic-sorting motif found in Cig57. Further, knockdown experiments showed that 
clathrin recruitment to the CCV by Cig57 was important for promotion of full vacuole 
expansion.  
Two different studies followed up on the multi-vacuolar phenotype of Cig2. The 
first study showed that Cig2 binds to two host lipids PI[45]P and phosphatidylserine 
(PS) on the CCV to co-opt the autophagy machinery and promote homotypic fusion 
[46].  This same study also used the G. mellonella model to show the in vivo requirement 
of Cig2 for pathogenesis of C. burnetii. The second study by a different research group 
highlighted the role of Cig2 in promoting host autophagy and recruitment of autophagy 
receptors onto the CCV [47]. These studies of both Cig57 and Cig2 are notable in the 
field of C. burnetii for being two of the few instances where a molecular mechanism was 
attributed to the role of a secreted effector.  
Nuclear Effectors 
Recently, the importance of a new class of secreted effectors that impact nuclear 
processes, termed nucleomodulins, have emerged. Nucleomodulins have been shown to 
be intimately involved in controlling the host cell gene expression, RNA splicing, DNA 
replication and repair, and chromatin remodeling for the benefit of the bacteria [48]. A 
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notable example of a well-characterized nucleomodulin is LntA from Listeria 
monocytogenes. This effector has been shown to control innate immune responses to 
infection by binding to the chromatin-silencing complex BAHD1, which prevents it 
from binding to promoter regions of interferon-stimulated genes (ISGs) [49]. This allows 
an increase in chromatin unwinding and acetylation of histone H3 and an upregulation of 
ISG expression, a response that has been shown to be in favor of the bacteria [50, 51].  
A specific class of nucleomodulins, termed cyclomodulins, has the ability to 
affect host cell cycle and have also shown to be important for the bacteria survival in a 
host cell [52, 53]. The most well-characterized of this class is the effector Cif, cycle-
inhibiting factor. This effector is secreted by both Enteropathogenic Esherichia coli 
(EPEC) and Enterohemolytic E. coli (EHEC), causative agents of bacterial diarrhea. 
This effector blocks cellular mitosis by preventing Cdk1 action, arresting cells in the 
G2/M stage of cell cycle [54]. Both LntA and Cif are only two examples of bacterial 
secreted effectors that modulate the host nucleus, but they highlight the importance of 
this novel class.  
There are six effectors in C. burnetii that have been published to have nuclear 
localization when a tagged version is transiently transfected into host epithelial cells 
[31]. Those effector proteins are: CBU0129, CBU0388, CBU0393, CBU0794, 
CBU1314 and CBU1524. Although not identified in that initial screen, AnkG was 
shown to exhibit nuclear trafficking in its role in preventing apoptosis [55].  Prior work 
described a potential role CBU1314 may play in modulating transcription [56], although 
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these results have not been fully confirmed. Another study has elucidated a role for 
CBU1524, named CaeA (Coxiella anti-apoptotic effector A), in preventing apoptosis 
when transiently expressed in epithelial cells [57]. A subsequent study demonstrated that 
CaeA contains an EK (glutamic acid/lysine) motif that is required for inhibiting 
apoptosis [58]. In addition, the authors found that expression of CaeA resulted in the 
upregulation of Survivin, a protein inhibitor of caspases that prevents apoptosis. 
Although no mutation has been reported for CaeA, AnkG or CBU1314 to test their role 
during infection, there is potential that they represent crucial effector proteins. Arguably, 
the presence of seven unique T4SS effector proteins in the nucleus supports the 















THE COXIELLA BURNETII TYPE IV SECRETION EFFECTOR CBU0794 
INTERACTS WITH HOST NUCLEAR PROTEIN TBL1XR1 
 
Synopsis 
Coxiella burnetii is an obligate intracellular pathogen and the causative agent of 
Q fever. One of the main virulence factors to promote survival and replication inside 
host cells is the type 4b (dot/icm) secretion system. Using ectopic localization of 
transfected HeLa cells, we previously identified 6 T4SS effectors that localize to the 
nucleus. To investigate the functionality of one of these, CBU0794, we deleted the 
bioinformatically-predicted nuclear localization signals (NLSs). This revealed a single 
NLS required for nuclear translocation. Furthermore, protein interaction studies revealed 
a novel interacting partner, TBL1XR1, a key transcriptional regulator. Consequences of 
this interaction are still yet to be determined, but they could provide insight to important 












C. burnetii is a Gram negative intracellular bacterium and the causative agent of 
the zoonotic disease, Q fever. The organism is spread through transmission of 
contaminated animal products, commonly by aerosols. Although the organism primarily 
targets alveolar macrophages, it can spread and infect other tissue types. Aerosol 
transmission, high infectivity, and stability in the environment resulted in its 
classification as a category B select agent and potential bioterrorist threat.  
 Once inside the host cell, C. burnetii employs its type IVB secretion system 
(T4SS) that secrete effector proteins to help establish its intracellular niche. While over 
100 potential secreted proteins have been identified [45], most of them lack much data as 
to their function. While new genetic tools have allowed some genetic mutant screens, 
most functional data we have for these effectors come through ectopic expression. This 
allows us to specifically query the direct effects of the protein itself without relying on 
complicated infection dynamics including host response and nutritional requirements. 
While this has an array of caveats, ectopic data has allowed more functional data to be 
understood [56, 59].  
CBU0794 (Cig20) was initially identified as a T4BSS effector because the 
promoter region has a predicted PmrA binding site, suggesting this gene is co-regulated 
with icm genes [42]. Our lab previously demonstrated that CBU0794 localizes to the 
nucleus when transiently transfected into HeLa cells [31]. In this study, we further 
investigated the nuclear interactions affected by CBU0794. Here we show that 
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CBU0794 trafficking to the nucleus is dependent on a single canonical nuclear 
localization signal, where it then interacts with TBL1XR1, which has multiple roles in 
transcriptional regulation. We also show the yeast genetic profile interactions using an 
epistasis mini-array profile (EMAP) screening assay.  
 
Materials and Methods 
Cell Lines and Strains. Strains used in this study are listed in Table 3.2. C. burnetii 
Nine Mile phase II (strain RSA439, clone 4). HeLa cells were used for microscopy 
experiments and HEK293T cells were used for protein pulldown and RNA-seq. 
Cloning and plasmids. Bioinformatic predictions of nuclear localization signals were 
generated using cNLSmapper (http//nls-mapper.iab.keio.ac.jp/) and/or NLStradamus 
(http://www.moseslab.csb.utoronto.ca/NLStradamus/). Nuclear export signals were 
identified through the online bioinformatics tool NetNES 1.1 Server 
(http://www.cbs.dtu.dk/services/NetNES/). Coiled-coil prediction was found using 
SMART (http://smart.embl-heidelberg.de/help/smart_glossary.shtml) [60]. Genes were 
amplified by PCR using Accuprime Pfx. PCR products were inserted into the specific 
plasmid using the In-Fusion system (BD Clontech).   
Cell transfection and Inhibitor Treatment. For ectopic expression in mammalian 
cells, HeLa cells (ATCC CCL-2) were seeded at 60% confluence in a 24-well plate. The 
following day, cells were transiently transfected with Lipofectamine 3000 according to 
manufacturer’s protocol. For treatment with Importazole (Sigma-Aldrich), cells were 
transfected for eleven hours following addition of 10μM for 1 hour before fixing.  
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Fluorescence Microscopy. At indicated timepoints, cells were fixed with 4% 
paraformaldehyde in PBS at room temperature for 10-15 minutes.  After fixation, cells 
were rinsed in PBS and quenched with 50mM ammonium acetate at room temperature 
for 10 minutes. Coverslips were then incubated in blocking buffer (0.02% Saponin in 
PBS with 10% horse serum) for 30 minutes in the dark. After blocking, the coverslips 
were incubated in the dark with primary antibody diluted in blocking buffer for 1hr at 
room temperature in the dark. Coverslips were then rinsed and incubated for another 
hour with each indicated secondary antibody as needed. To visualize the nucleus, 
coverslips were stained with 10 mg/mL of Hoescht in water for 10 minutes before a final 
wash with water. Coverslips were mounted on slides with Mowiol and imaged with a 
Nikon A1 confocal microscope. The Nikon elements software was used for image 
analysis and quantification. 
Protein pulldown. 293T cells were transfected for 24 hours before washing with PBS + 
0.5M EDTA.  Washed cells were lysed in cell lysis buffer (cell signaling) with protease 
inhibitor cocktail (cell signaling) and PMSF. GFP resin bead were washed with wash 
buffer containing 1M Tris pH 7.4, 5M NaCl, 0.5M EDTA, and 20% NP40. Lysates were 
incubated with anti-GFP beads from the GFP-trap kit (Chromtek) according to the 
manufacture’s protocol. Elution was boiled in 2X Sample buffer (Bio-Rad) and 
supernatant was used. Protein bands were visualized by Silver Stain (Fisher Scientific) 
before being analyzed by mass spectrometry. 
Western Blotting. Cell lysates were run on a SDS-page gel at 100V for 60 minutes 
before wet transfer to a PVDF membrane. Immunoblots were performed using rabbit 
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anti-TBL1XR1 (abcam or Thermo Fisher), or rabbit anti-SMRT (abcam), or rabbit anti-
NCoR (abcam) at a 1:5000 dilution. Mouse anti-actin (abcam) was used at a 1:5000 
dilution for a loading control. Goat monoclonal anti-mouse (LICOR) and donkey 
monoclonal anti-rabbit (LICOR) were used at dilutions of 1:10000.  
Quanitative RT-PCR. Cells were harvested with TRIzol (Thermo Fisher) and RNA 
was isolated using a spin column (Machery-Nagel). We made cDNA with the High-
capacity Reverse-transcriptase kit (ABI) before using Fast SYBER green (Thermo 
Fisher) master mix to analyze for specific transcripts in each sample.  
RNA-seq. 293T cells were transfected with each construct using PolyJet according to 
the manufacturers protocol. After 24 hours, cells were treated with Trizol (Invitrogen). 
Library preparation and sequencing was done at the Texas A&M Institute for Genome 
Sciences and Society (TIGSS) in College Station, TX. Analysis used either Mock 
transfected or GFP as a baseline for identifying differentially expressed transcripts with 
either a 2-fold or 3-fold log increase or decrease.  
Yeast toxicity and EMAP analysis. The toxicity assay and EMAP analysis was 
performed as previously described [61]. Results were determined from at least three 
independent experiments.  
Statistical Analyses. Statistical analysis was performed with Prism (GraphPad Software, 







Table 2.1. Bacterial strains and plasmids used in this study 
_______________________________________________________________________ 
Strain or Plasmid   Description    Source 
_______________________________________________________________________ 
Strains 
   E. coli DH5α    F– Φ80lacZΔM15 Δ(lacZYA-argF)      Stratagene
    U169 recA1 endA1 hsdR17 (rK–, mK+)  
phoA supE44 λ– thi-1 gyrA96 relA1 
 
   E. coli Stellar Cells  F–, endA1, supE44, thi-1, recA1, relA1     Clontech 
 
Δ(lacZYA - argF) U169, Δ(mrr - hsdRMS - mcrBC)  
ΔmcrA, λ– 
 
   C. burnetii Nine Mile (RSA439) Phase II, Clone 4 
 




   pEGFP-C1    C-terminal fusion to EGFP, Kan
r
         Clontech 
   pEGFP-C1 0794   CBU0794 cloned into pEGFP-C1        [31] 
   pEGFP-C1 0794ΔNLS1  CBU0794Δ NES cloned into pEGFP-C1  this study 
   pEGFP-C1 0794ΔNLS2   CBU0794Δ NLS cloned into pEGFP-C1  this study 




 Table 2.2. Oligonucleotides used in this study 
_______________________________________________________________________ 
Oligonucleotide  Oligonucleotide Sequence (5’-3’)  Application 
_______________________________________________________________________ 
in794dNLS1 Sal F1 GAATTCTGCAGTCGACATGAAAATTATT     Infusion  
 AAATTAGTGGAA    deletion of the NLS1    
in794dNLS1 Sal R1 TATAGACGAGATAGAGTCTTGAGCTGCTCTATAC 
in794dNLS1 Sal F2 TCTATCTCGTCTATAGATGAA 
in794dNLS1 Sal R2 CCGCGGTACCGTCGACTTATCTAAATCTGGCTTTTTGC 
in794dNLS2 Sal F1  GAATTCTGCAGTCGACATGAAAATTA           Infusion 
TTAAATTAGTGGAA          deletion of NLS2 
in794dNLS2 Sal R1 TTCATCCTTATCTCTCGCTTGTCGTGTTCATCAC 
in794dNLS2 Sal F2 AGAGATAAGGATGAACTCCA 
in794dNLS2 Sal R2 CCGCGGTACCGTCGACTTATCTAAATCTGGCTTTTTGC 
in794dCC Sal F1 GAATTCTGCAGTCGACATGAAAATTATTAAA        Infusion 
TTAGTGGAA             deletion of CC domain 
in794dCC Sal R1 TCTTTTTCTAATTCGAAAAAGAGATGCAAAACTTTAAA 
in794dCC Sal F2 CGAATTAGAAAAAGAAAATTATTA 
in794dCC Sal R2 CCGCGGTACCGTCGACTTATCTAAATCTGGCTTTTTGC  
794in Tn7HA F ATTTACGCGTGAATTCATGAAAATTAT   Infusion with 
TAAATTAGTGGAA             EcoRI site into 
  pTN7 TetRA 3xHA 
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Table 2.2. Oligonucleotides used in this study continued. 
_______________________________________________________________________ 
Oligonucleotide  Oligonucleotide Sequence (5’-3’)  Application 
_______________________________________________________________________               
794in Tn7HA R GCTTCTCGAGGAATTCTTATCTAAATCTGGCTTTTTGC 
hGAPDH F  GGAGCGAGATCCCTCCAAAAT    qPCR 
hGAPDH R  GGCTGTTGTCATACTTCTCATGG   qPCR 
hNCOR2 F  CACGAGGTGTCAGAGATCATCG   qPCR 
hNCOR2 R  GCCATAAGCCCGTTCATGTTG    qPCR 
mNCOR2 F  GATGACCCCATGAAGGTCTACA   qPCR 
mNCOR2 R  GGCCAAAGTTCTTAGGGTGCT    qPCR 
mIL6 F  CCAAGAGGTGAGTGCTTCCC    qPCR 
mIL6 R  CTGTTGTTCAGACTCTCTCCCT    qPCR 
mCXCL2 F  CCAACCACCAGGCTACAGG    qPCR 
mCXCL2 R  GCGTCACACTCAAGCTCTG    qPCR 
hTBL1XR1 F  CACCCGCTGCATTGATTTCTA    qPCR 
hTBL1XR1 R  TACGGCATCTATCAGGGACAG    qPCR 
mTBL1XR1 F  TGCAAGCACACCTGACAAGTT    qPCR 
mTBL1XR1 R CTCCTGTGAATCCAGCTTCTG    qPCR 
 hNCOR1 F  ACACCGCAGTATTGTCCAAAT    qPCR 
hNCOR1 R  CACCTGGTTTGTCTTGATGTTCT   qPCR 
mNCOR1 F  ACAGAGCAAAGTCGTTATCCTTC   qPCR 
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Table 2.2. Oligonucleotides used in this study continued. 
_______________________________________________________________________ 
Oligonucleotide  Oligonucleotide Sequence (5’-3’)  Application 
_______________________________________________________________________               




CBU0794 is expressed during C. burnetii infection. In order to assess the expression 
level of CBU0794, we designed gene specific primers and quanitifed expression both 
during ACCM-2 growth and different timepoints during infection. As shown in Figure 
2.1, expression of CBU0794, in J774A.1 macrophages, appears to be consistent at both 2 
and 4 days post infection. The amount of gene expression in cell infection is similar to 
the amount seen when grown axenically in ACCM-2 medium. Since the time of 
performing this experiment, a separate microarray study [62] was published that 
analyzed the expression of the entire C. burnetii genome during infection of Vero cells. 
In this study, the authors compared gene levels at 5, 7, 14, and 21 days post infection, 
with day 3, serving as an early baseline. Interestingly, this study found that the levels of 
CBU0794 are higher early in infection and by 5 days are 1.5 fold decreased. This 
decreased level then stays throughout the remainder of infection. With these results, it 
would seem that CBU0794 is needed earlier during infection and then expression is 
dampened later when it is no longer needed. Because I used J774A.1 macrophages in 
 
 19 
these experiments, it is impossible to look that late during infection. J774A.1 overgrow 
and die too quickly in a tissue culture dish which can limit our interpretations. Taken 




Figure 2.1. CBU0794 gene expression in infection and ACCM-2 growth shows 
constitutive levels. Quantitative PCR was done using gene specific primers for either 
Com1 or CBU0794. Graph shows number of mRNA copies per genome of C. burnetii 
present in either ACCM-2 growth cultures, or infected J774A.1 macrophages at either 
D2 or D4 post-infection.  
 
The effector CBU0794 utilizes a nuclear localization sequence to traffic to the 
nucleus. Using bioinformatic analysis, we sought to identify the sequence required for 
the nuclear localization of CBU0794. Two different NLS domain algorithms, 
 
 20 
NLStradamus [63] and cNLSmapper [64] each identified a unique potential NLS (Figure 
2A). To test the contribution of these two domains on nuclear localization, we deleted 
each one individually and queried the nuclear localization of the generated CBU0794 
alleles. Our results show that while NLS1 partially contributes to the nuclear 
localization, NLS2 is essential for CBU0794 to be directed to the nucleus. Moreover, 
this localization is dependent on the canonical nuclear import pathway.  When the 
nuclear import receptor, Importin-β, is blocked with the pharmacological inhibitor 
Importazole, the nuclear localization of CBU0794 was inhibited, suggesting that this 





Figure 2.2. CBU0794 contains a canonical nuclear localization signal. Quantitation 
of Importazole treatment during transfection of CBU0794 in HeLa cells.  Predicted 




CBU0794 contains an essential nuclear localization sequence. To fully understand the 
essential elements for CBU0794’s localization to the host cell nucleus, we individually 
deleted the two predicted nuclear localization sequences. The results, seen in Figure 3, 
were surprising. Deletion of the first predicted NLS partially contributed to the nuclear 
localization phenotype, about 50%. The second NLS, however, seemed to be more 
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responsible for the phenotype, as deletion of this region alone almost completely 
abolished the nuclear localization pattern. Alternately, it is possible given this result that 




Figure 2.3. Contributions of predicted NLSs to CBU0794 nuclear localization. 
Confocal images of transfections of vector, full-length CBU0794, and deletion mutants 
from each predicted NLS. Images are representative from across at least three 





Deletion of the coiled-coil region alters the stability of the protein. Using the 
bioinformatics prediction software SMRT, we also discovered that CBU0794 contains a 
predicted coiled-coil motif. A coiled-coil is a structural motif consisting of two to five 
helices forming a supercoil, often involved in protein interactions [65]. To understand 
the contribution of this region on protein functionality, we deleted the region encoding 
the coiled-coil sequence. The protein lacking a coiled-coil region appeared to be unable 
to localize to the nucleus during transient transfection. This may be due to instability of 
the protein when this region is absent. The central location of the coiled-coil domain, as 
well as the key role it plays on the folding of the protein, likely results in an unstable or 
misfolded protein. In localization studies using the ΔCC mutant, the protein appeared 
lightly punctate in the cytoplasm and was very faint. Given that it is a key structural 
element of this protein, deletion probably caused improper folding causing it to be 
degraded in the cytoplasm. This would correlate with the lower expression of this mutant 









Figure 2.4. Deletion of the coiled-coil region of CBU0794 also prevents nuclear 
localization of the protein. Quantitation of deletions of NLS1, NLS2, and Coiled-coil 
region (CC) compared to full-length CBU0794. Confocal image shown is representative 




EMAP analysis points to a role for CBU0794 in transcription. In order to understand 
functionality, CBU0794 was included in a collaborative Epistatis Miniarray profile 
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project (EMAP) [61]. EMAP uses S. cerevisiae to express a protein of interest, which is 
then mated to individual yeast mutants. The resulting data provides a profile of genetic 
interactions that are similar to the expression of the protein. Therefore, you can predict 
pathways that your protein may be involved to generate an impactful hypothesis.  
 
 
Figure 2.5. EMAP data analysis of CBU0794. (A) Enriched GO terms for significantly 
correlating genetic interaction profiles for CBU0794. (B) HeLa cells transiently 
transfected to express GFP-CBU0794, co-stained with Hoechst to visualize nuclei. Scale  
Figure 2.5 cont. bar, 10μm. Figure adapted from Patrick and Wojcechowskyj, et al. 





In the case of CBU0794, the genetic interaction pathways, seen in Figure 2.5, supports 
an involvement with the nucleosome. The nucleosome is a term for a unit of DNA coiled 
around histones. This data shows that expression of CBU0794 correlates with mutants in 
chromatin or histone biology. 
 
 
Table 2.3. Mass Spectrometry Results of CBU0794 Immunoprecipitation. Unique 
protein mass spectrometry for CBU0794-GFP pulldown listed in order of relative 




CBU0794 interacts with TBL1XR1 in vitro. To assess protein interactions, we did a 
pulldown using GFP-tagged CBU0794 expressed in 293T cells. Mass spectrometry 
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analysis predicted several potential protein interactions with a subset of proteins 
involved in eukaryotic transcription (Table 2.3). It is interesting to note that all of the 
proteins from the mass spectrometry results listed in the table are nuclear proteins 
associated directly with DNA. Four of these seven proteins were tested by western blot 
to confirm protein interaction during CBU0794 pulldown. Confirmation of the mass 
spectrometry showed that CBU0794 does indeed interact with TBL1XR1, a key 
component of the SMRT/NCoR-HDAC3 complex (Figure 2.6). Protein interactions with 
other proteins tested could not be confirmed. Individual western blots probed for the 
other proteins on the list failed to confirm the mass spectrometry results (data not 
shown).  
Transducin (β)-like X-linked receptor 1 (TBL1XR1) contains both a F-box as 
well as WD-40 repeats [66]. It is best characterized as a transcriptional activator for the 
SMRT/NCoR-HDAC3 repressor complex, regulating gene activation and repression. It 
participates in the complex by facilitating interaction with histones, with another protein 
TBL1, which was once thought to be functionally redundant with TBL1XR1 [67]. 
Interestingly, though they may share some functional redundancy, they also respond to 
individual upstream signaling [68]. Despite having a high degree of protein homology, 
their activities are regulated through differential phosphorylation [69].   
TBL1XR1, through the SMRT/NCoR complex, is involved in regulating gene 
expression for multiple upstream signaling pathways including: activator protein-1 (AP-
1), retinoic acid receptor (RAR), peroxisome proliferator-activated receptor γ (PPARγ), 
estrogen receptor (ER), thyroid hormone receptor (T3R) and NF-κB, [70]. Mutations of 
 
 28 
TBL1XR1 in human cells can result in numerous mental and physical developmental 
issues, including mental retardation and tumors [71].  
TBL1XR1 can be present in both the cytoplasm or nucleus [68] but the 
CBU0794 interaction appears to occur in the nucleus. The interaction of CBU0794 and 
TBL1XR1 is dependent on the nuclear localization of CBU0794, as deletion of the NLS 
abolished this interaction. When we repeated the pulldown with the NLS mutant that 
does not go to the nucleus, the interaction with TBL1XR1 is no longer present. We can 
hypothesize that this protein interaction occurs after CBU0794 enters the nucleus since 
the NLS mutant doesn’t interact with TBL1XR1. It could be, however, that just the 




Figure 2.6. Western blot confirmation of CBU0794 immunoprecipitation confirms 
interaction with TBL1XR1. Input and Elution of GFP immunoprecipitation for  
Figure 2.6 cont. pEGFPC1 vector, CBU0794 and CBU0794ΔNLS was subjected to a 







Figure 2.7. Hypothesis for implications of CBU0794 and TBL1XR1 interaction. Our 
primary hypothesis to test was one in which CBU0794 interacts with TBL1XR1 to 








Figure 2.8. Expression of CBU0794 Does Not Effect Transcription or Protein Levels 
of the SMRT/NCoR Complex. (A) Gene expression analysis in 293T cells during 
transfection conditions with respective constructs. Graphs are mean + SD of three 
independent experiments. (B) Representative graphs of western blot analysis in 293T 




Interaction of CBU0794 and TBL1XR1 does not alter gene expression or protein 
levels of the SMRT/NCoR complex components. Because TBL1XR1 is involved in 
multiple transcriptional pathways, follow-up analysis proved to be difficult. The first 
step in evaluating CBU0794’s effect of the SMRT/NCoR pathway was to look at its 
effect on protein levels of core components of this pathway. To do this, we expressed 
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CBU0794 and the NLS mutant in 293T cells, as done in previous protein interaction 
studies. We then analyzed protein levels of TBL1XR1, SMRT, and NCoR in these cells. 
As seen in Figure 2.8, there did not appear to be a significant difference in expression of 
the protein of interest when CBU0794 was expressed compared to vector or untreated 
cells. There was also no change in transcript levels of these genes under the same 
conditions.  
In addition to its crucial role in the SMRT/NCorR pathway, TBL1XR1 has been 
shown to be important for transcription through the Wnt-β-catenin signaling pathway 
[72]. The Wnt/β-catenin pathway is involved in many cellular processes such as 
development, stem cell proliferation and tumorigenesis [73]. It has been shown that 
TBL1XR1 is SUMOylated as a result of upstream Wnt signaling, thus removing the 
protein from the SMRT/NCoR complex. It then forms a new TBL1XR1-TBL1-β-catenin 
complex causing transcriptional activation of Wnt-regulated genes [74]. Although there 
is no evidence of modulation of the Wnt/β-catenin pathway during infection by C. 
burnetii, it has been demonstrated by a number of other bacteria, including E. 
chaffeensis and M. tuberculosis [75, 76].    
We hypothesized that CBU0794 causes SUMOylation of TBL1XR1 in the 
absence of Wnt signaling to dissociate it from the SMRT/NCoR pathway. This could be 
either direct or indirect post-translational modification in the presence of CBU0794. 
Interestingly, when we compared cell lysates by western blot we observe a small 
population of protein reacting with the TBL1XR1-specific antibody that is shifted to a 
higher molecular weight (Figure 2.9). Because most TBL1XR1 migrated at the correct 
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size, this modification occurs in a minority of the TBL1XR1 population. Importantly, 
though, this band only appears when CBU0794 is expressed; both vector and CBU0794 




Figure 2.9. Potential model of CBU0794 and TBL1XR1 involved in Wnt signaling.  
(A) Hypothesized model by which interaction of TBL1XR1 and CBU0794 cause an 
impact on Wnt gene transcription. (B) Western blot of TBL1XR1 in transfection  
Figure 2.9 cont. conditions show a small fraction of TBL1XR1 that has been modified 
in the presence of CBU0794.  
 
Further testing must be done to determine if this is a result of SUMOylation or 
some other post-translational modification. TBL1XR1 can be post-translationally 
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modified in other ways, including phosphorylation [69]. We also lacked a positive 
control to show SUMOylation of TBL1XR1.  
Expression of CBU0794 alone does not appear to change transcriptional levels of 
any host proteins. In order to assess whether or not CBU0794 has an effect on global 
transcription, we performed an RNA-seq in 293T cells. We compared transcriptional 
profiles of vector, CBU0794 and CBU0794 ΔNLS transfected cells. A mock-transfected 
sample was also used for additional baseline comparison. Each condition was performed 
in triplicate. The heat map of transcriptional changes (Figure 2.10) indicated that there is 
not a lot of variation among transcript levels. The largest difference is a transcriptional 





Figure 2.10. Heat map of RNA-seq of all three replicates showing fold-change of 
differentially expressed transcripts in each sample. RNA-seq samples were analyzed 
for a 2-fold change in transcription levels. Each condition was done in triplicate in 




Additionally, looking at a Venn diagram (Figure 2.11) of up- and down-regulated 
genes that have at least a 2-fold change, there not a significant difference between 
samples. Only 5 genes are up-regulated in response to CBU0794 expression. There are 
15 genes are down-regulated under CBU0794 expression conditions, with an additional 
9 genes also down-regulated during the mock transfection. From this data, it is difficult 
to conclude whether there is an active transcriptional response induced by transfection of 




(A)      (B) 
 
 
Figure 2.11. Venn diagram of RNA-seq showing differentially expressed transcripts 




The biggest caveat to this experiment is that we tested transfection conditions 
instead of infection. The lack of a CBU0794 mutant strain prevents an infection-based 
comparison. Although we did not observe transcriptional differences in our experiment, 
that does not suggest that CBU0794 is not involved in transcriptional modulation. We 
did the RNA-seq under normal transfection conditions. We may have needed an external 
stimulus to be present in order to induce any transcriptional modulation.  
 
Discussion 
A growing body of literature has highlighted the importance of Nucleomodulins, 
bacterial proteins that interfere with host nuclear processes [48]. While previous 
observations have revealed six potential C. burnetii nucleomodulins, this is the first in 
depth analysis to characterize an effector with nucleomodulin activity.   
Protein interaction analysis predicted that CBU0794 interacts with the eukaryotic 
transcriptional regulator TBL1XR1 in the host cell’s nucleus. Therefore, we propose a 
model where upon infection by C. burnetii, the Type IV secretion machinery is activated 
and secretes CBU0794 into the host cell. Using canonical nuclear import, CBU0794 
traffics into the host nucleus where it interacts with its protein partner TBL1XR1. This 
interaction was confirmed by western blot analysis. Co-localization studies between 
CBU0794 and TBL1XR1 could further validate this finding. Consequences of this 
interaction are yet to be determined, but it could have wide reaching effects on host 
transcription in response to upstream signaling events.  
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We showed that CBU0794 interacts with the regulator protein TBL1XR1. This 
protein is involved in multiple transcriptional responses, all of which require an 
extracellular stimulus. If CBU0794 were indeed interacting with TBL1XR1 to 
manipulate this transcriptional response, you wouldn’t see an effect without the stimulus 
being present. In normal cellular conditions, TBL1XR1 is bound as a repressor to the 
SMRT/NCoR complex. The addition of a nuclear hormone receptor causes a 
conformational change that removes TBL1XR1 from the SMR/NCoR complex allowing 
transcription to occur.  
Future studies will focus on the impact of CBU0794 on pathogenesis of C. 
burnetii. Despite the DNA sequence of CBU0794 being very AT-rich, transposon 
mutagenesis has failed to produce a CBU0794 mutant. This may be due to an essential 
functionality of this protein for the viability of the organism. More likely, a mutant could 
be made non-viable due to its location among essential t-RNAs in the C. burnetii 
genome. A more targeted approach needs to be done to make a site-directed CBU0794 
mutant, which will determine if this mutant would be viable. With this mutant, we can 
further assess the contribution of CBU0794 to pathogenesis in both intracellular studies 
as well as a mouse model. A CBU0794 mutant will also allow us to further study the 








NUCLEAR TRANSLOCATION OF COXIELLA BURNETII T4SS EFFECTOR 
CBU0388 IS REQUIRED FOR PATHOGENESIS 
 
Synopsis 
Coxiella burnetii is a Gram negative, obligate intracellular pathogen and the 
causative agent of the zoonotic disease Q fever. This organism utilizes an essential type 
IVB secretion system (T4BSS) to translocate effector proteins into the host cell to 
promote its own intracellular survival and replication. To date, over 100 effector proteins 
have been identified but not much is known about their functionality. Here we 
demonstrate the nuclear trafficking of one such effector, CBU0388, which is essential 
for replication of C. burnetii both in vitro and in vivo.  Trafficking both in and out of the 
nucleus appear to be important for its mechanism of action within the host cell. We show 
that this trafficking is dependent on both a nuclear localization signal (NLS) and a 
nuclear export signal [49]. This is the first instance of a nuclear-localized effector 
required for pathogenesis in C. burnetii.   
Introduction 
Coxiella burnetti is a gram-negative obligate intracellular pathogen and the 
causative agent of Q fever, a zoonotic disease transmitted from aerosols of infected 
livestock. Because of its low infectious dose, environmental stability, and aerosol route 
of transmission, C. burnetti is classified as a category B select agent. While C. burnetii 
primarily infects alveolar macrophages after inhalation, it is capable of infecting a 
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variety of host cells, including phagocytic and non-phagocytic cells. Once inside the cell, 
the bacteria set up a replicative niche called the Coxiella-containing vacuole (CCV) 
where they need an acidic pH in order to promote replication. C. burnetii utilizes a 
Dot/Icm secretion system to deliver over 100 effectors into the host cell, creating a 
unique replicative niche for itself. Remodeling of the CCV is essential for survival of C. 
burnetii inside a hostile lysosome-like compartment.  
Several bioinformatics and functional screens have been performed by our lab 
and others to identify potential secreted effector proteins [31, 42, 77]. To date, over 100 
T4SS effectors have been described for the virulent Nine Mile strain of C. burnetii. With 
only a handful of effectors having been characterized so far, there is a huge gap in 
knowledge to understand how C. burnetii modulates its host environment to survive.  
Here, we describe one effector, CBU0388, which is necessary for CCV 
biogenesis and replication. In addition, it appears to be required for in vivo pathogenesis 
of the organism in a SCID mouse model of infection. Once secreted into the cytoplasm, 
CBU0388 traffics through the host nucleus using both a canonical nuclear localization 
signal and nuclear export signal.  
Materials and Methods 
Cell Lines and Strains. Strains used in this study are listed in Table 3.2. C. burnetii 
Nine Mile phase II (strain RSA439, clone 4). HeLa cells were used for all the 
transfection experiments.  
Cloning and Plasmids. Bioinformatic predictions of nuclear localization signals were 
generated using cNLSmapper (http//nls-mapper.iab.keio.ac.jp/) and/or NLStradamus 
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(http://www.moseslab.csb.utoronto.ca/NLStradamus/). Nuclear export signals were 
identified through the online bioinformatics tool NetNES 1.1 Server 
(http://www.cbs.dtu.dk/services/NetNES/). 
Transformation and Growth of C. burnetii. C. burnetii was axenically cultured in 
ACCM-2 media as previously described [40]. Competent cells were made my spinning 
down and washing in sterile water with 10% glycerol. For transformation, C. burnetii 
was resuspended with sterile water before electroporation with 10-20ug of plasmid at 
1800V, 400Ω in a 0.2cm cuvette.  Where appropriate, 350 μg/mL of kanamycin or 5 
μg/mL of chloramphenicol was added for selection. For anhydrotetracycline induction, 
50 ng/mL was added for 24 hours as done previously [78].  
Cell transfection and Inhibitor Treatment. For ectopic expression in mammalian 
cells, HeLa cells (ATCC) were seeded at 60% confluence in a 24-well plate. The 
following day, cells were transiently transfected with Lipofectamine 3000 according to 
manufacturer’s protocol. For treatment with Importazole (Sigma-Aldrich), cells were 
transfected for eleven hours following addition of 10μM for 1 hour before fixing. For 
Leptomycin B (InvivoGen) treatment, cells were transiently transfected for 8 hours 
before addition of 50nM to each well for 4 hours.  
Fluorescence Microscopy. At indicated timepoints, cells were fixed with 4% 
Paraformaldehyde in PBS at room temperature for 10-15 minutes.  After fixation, cells 
were rinsed in PBS and quenched with 50mM ammonium acetate at room temperature 
for 10 minutes. Coverslips were then incubated in blocking buffer (0.02% Saponin in 
PBS with 10% horse serum) for 30 minutes in the dark. After blocking, the coverslips 
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were incubated with primary antibody diluted in blocking buffer for 1hr at room 
temperature in the dark. Coverslips were then rinsed and incubated for another hour with 
secondary antibody. To visualize the nucleus, coverslips were stained with Hoescht in 
water for 10 minutes before a final wash with water. Coverslips were mounted on slides 
with Mowiol and imaged with a Nikon A1 confocal microscope. The Nikon elements 
software was used for image analysis and quantification. 
Western Blotting, Cell Fractionation, and Immunoprecipitation.  Immunoblots were 
performed using anti-HA high affinity rat monoclonal antibody (Roche; 3F10). Goat 
monoclonal anti-rat (LICOR) and goat monoclonal anti-mouse (LICOR) were used at 
dilutions of 1:10000. 
C. burnetii Growth Curves. Bone marrow derived macrophages were acquired from 
BL6 mice as described (paper reference). SCID mouse infection were done as published 
previously [34]. HeLa cells were seeded in 24-well plates at a density of 5 x 10
4
 per 
well. The following day, the indicated strains of C. burnetii were used to infect at a MOI 
of 50. The MOI was calculated using the Quanti-iT PicoGreen dsDNA Assay kit (Life 
Technologies). Cells were centrifuged at 500xg for 10 minutes before placing in the 
37°C incubator for one hour. After incubation, the cells were washed three times and the 
media was replaced with DMEM with 10% FBS. At day 1, 4, and 7, cells were lysed in 
DNA lysis buffer (1M Tris, 0.5M EDTA, Lysozyme, Glucose) with Proteinase K. 
Genomic DNA isolated from the samples using the Roche High Pure PCR Template 
Prep kit (Indianapolis, IN) according to the manufacturer’s protocol. Resulting genomic 
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DNA was quantified through qPCR specific for either the IS1111 insertion sequence or 
Himar transposon as described previously [34].  
Statistical Analyses. Statistical analysis was performed with Prism (GraphPad Software, 
Inc.) using an unpaired, Student’s t-test. *P<0.05, **P<0.01. 
 
Table 3.1. Oligonucleotides used in this study 
_______________________________________________________________________ 
Oligonucleotide Oligonucleotide Sequence (5’-3’)   Application 
_______________________________________________________________________ 
388 NLS1del 1F GTCCGGACTCAGATCTATGAGATCAT  Infusion 
GGTTGTCGTT 
388 NLS1del 1R CGTCATCATTGCTGACTGGTTTTTTTA 
CCCACAAAT 
388 NLS1del 2F TCAGCAATGATGACGACATT 
388 NLS1del 2R CCGCGGTACCGTCGACTTAGCTTTTTTC 
AAAATTTACTTT 
388 NLS2del 1F GTCCGGACTCAGATCTCCAGATCTTTGTCGTTAC 
AAGCTATTGAGAAACT 
388 NLS2del 1R AACCTTTTGAAAAATATTTCATTTTGCG 
CAGAATAAA 




Table 3.1. Oligonucleotides used in this study continued 
_______________________________________________________________________ 
Oligonucleotide Oligonucleotide Sequence (5’-3’)   Application 
_______________________________________________________________________ 
388 NLS2del 2R CCGCGGTACCGTCGACCCGTCGACGCTTTTTTC 
AAAATTTACTTTACGCT 
388 NLS3del 1F GTCCGGACTCAGATCTCCAGATCTTTGTC 
GTTACAAGCTATTGAGAAACT 
388 NLS3del 1R CTTGAGCTCGAGATCTCATTTTTATTGTTTTA 
AGCTCCACATC 
388 NLS3del 2F GAATTCTGCAGTCGACTCAGAAAATCTCGTTAA 
TCTTCCAC 
388 NLS3del 2R CCGCGGTACCGTCGACCCGTCGACGCTTTTTTCA 
AAATTTACTTTACGCT 
388 Tn7in F  ATTTACGCGTGAATTCATGAGATCATGGTTGTCGTT 
388 Tn7in R  GCTTCTCGAGGAATTCTTAGCTTTTTTCAAAATTTACTTT 
388 cDNA primer GTTTGAATTTCCGCTTGATTCTTATTTTTTCC 
388 cDNA F  TGAGATCATGGTTGTCGTTACA 
388 cDNA R  TTTGAATTTCCGCTTGATTCTT 
ObgE cDNA F AAGTCCACCTTCATCCATGC 
ObgE cDNA R CGCTAGCGCCTTAATTAAC 
rpmA cDNA F CTTGCGGGGAATATCATTGT 
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Table 3.1. Oligonucleotides used in this study continued 
_______________________________________________________________________ 
Oligonucleotide Oligonucleotide Sequence (5’-3’)   Application 
_______________________________________________________________________ 
rpmA cDNA R CGGCTCAATGGAGACAAAGT 
rplU cDNA F  GAGAAGTTGGCGCAAGATGT 
rplU cDNA R  TGCCGTTTCATGTGATGTTT 
cDNA up2 F  CTTCGCTTCATACGGGCTAC 
cDNA up2 R  CCTCCCCATTGAATCTCTCA 
cDNA up1 F  CCAACCGAGTTCGAAACAAT 
cDNA up1 R  CGTATATGGACCCACCCTTG 
AA912-39 1F  GTCCGGACTCAGATCTCCAGATCTTTGTCG          Deletion  
TTACAAGCTATTGAGAAACT                                      of NLS3 
AA912-39 1R  CTTGAGCTCGAGATCTCATTTTTAT 
TGTTTTAAGCTCCACATC 
AA912-39 2F  GAATTCTGCAGTCGACTCAGAAAATCT 
CGTTAATCTTCCAC 
AA912-39 2R  CCGCGGTACCGTCGACCCGTCGACGCTTT 
TTTCAAAATTTACTTTACGCT 
mCDK1 F  AGAAGGTACTTACGGTGTGGT 
mCDK1 R  GAGAGATTTCCCGAATTGCAGT 
mActin F  CGCCACCAGTTCGCCATGGA 
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Table 3.1. Oligonucleotides used in this study continued 
_______________________________________________________________________ 
Oligonucleotide Oligonucleotide Sequence (5’-3’)   Application 
_______________________________________________________________________ 
mActin R  TACAGCCCGGGGAGCATCGT 
 
Table 3.2. Bacterial strains and plasmids used in this study 
_______________________________________________________________________ 
Strain or Plasmid  Description     Source 
_______________________________________________________________________ 
Strains 
   E. coli DH5α    F– Φ80lacZΔM15 Δ(lacZYA-argF)   Stratagene
    U169 recA1 endA1 hsdR17 (rK–, mK+)  
phoA supE44 λ– thi-1 gyrA96 relA1 
Table 3.2. Bacterial strains and plasmids used in this study continued 
_______________________________________________________________________ 
Strain or Plasmid  Description     Source 
_______________________________________________________________________   
E. coli Stellar Cells  F–, endA1, supE44, thi-1, recA1, relA1 Clontech 
ΔmcrA, λ– 





Table 3.2. Bacterial strains and plasmids used in this study continued 
_______________________________________________________________________ 
Strain or Plasmid  Description     Source 
_______________________________________________________________________ 
C. burnetii Nine Mile (RSA439) Phase II, Clone 4 
 
   RSA439 MK DotA::Tn, Cm
r
 




   pEGFP-C1   C-terminal fusion to EGFP, Kan
r
           Clontech 
   pEGFP-C1 0388  CBU0388 cloned into pEGFP-C1   [31] 
   pEGFP-C1 0388Δ NES CBU0388Δ NES cloned into pEGFP-C1        this study 
   pEGFP-C1 0388 ΔNLS  CBU0388Δ NLS cloned into pEGFP-C1        this study 
   pST100   pUCR6K-miniTn7-Kan-TetRA-4xHA    [46] 
    Anhydrotetracycline-inducible 
expression cassette of 4xHA in the 
miniTn7-Kan transposon sequence- 








The effector CBU0388 is required for intracellular replication in multiple in vitro 
cell types. We previously described a transposon mutant in CBU0388 as having an 
attenuated growth in J774A.1 macrophages [31]. Here, we show that the CBU0388 
mutant is unable to replicate in any host cell, including macrophages and HeLa cells 
(Figure 3.1). In tissue culture cell infection with the CBU0388::tn mutant, C. burnetii 
cannot form an expansive vacuole, but instead is restricted in a tight vacuole where it 




Figure 3.1. CBU0388 appears to be necessary for C. burnetii replication in tissue 
culture cells. BMDMs or HeLa cells were infected with NMII, DotA::Tn, Cbu0388::Tn 
or CBU0388::Tn Comp and lysed for genome equivalents on D1, D4 and D7. Values are  
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Figure 3.1 cont. mean ±SD of triplicate experiments. Data was analyzed using a One-





CBU0388 is important for pathogenesis in vivo using a SCID mouse model. Using a 
SCID mouse model, the bacterial load at 10 days post-infection is significantly reduced 
in the CBU0388::tn mutant compared to wild type (Figure 3.2). The CBU0388::tn also 
cannot cause splenomegaly, a hallmark for productive pathogenesis in a SCID mouse 
model of C. burnetii infection [34]. This attenuation further suggests the important role 








Figure 3.2. CBU0388 is required in vivo pathogenesis in a SCID mouse model. (A) 
Genome equivalents calculated by qPCR from DNA purified from spleens at day 10 
post-infection (B) Splenomegaly for SCID mouse infection at day 10 post-infection 
calculated as spleen weight as a percentage of total body weight at the time of necropsy. 
Error bars are mean ±SD. Asterisks represent statistically significant reductions in 
genome copies (A) or spleen weight (B) when compared to wildtype NMII infection 
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Figure 3.3. Complementation was not achieved through trans-complementation in 
HeLa cells.  (A) Growth curve of C. burnetii strains in HeLa cells. The CBU0388::tn 
mutant was detected using a probe specific to the Himar1 in order to differentiate it from 
the WT bacteria. (B) Genome equivalents for each strain at 7 days post infection 
showing a modest growth of 1 log compared to CBU0388::tn alone, but not significant 




The effector CBU0388 may contribute to acute virulence. CBU0388 was an 
interesting protein to study for many reasons. Though we already had a transposon 
mutant showing a growth defect, we knew nothing about the protein itself. In order to 
understand more about the potential functionality of this protein, we looked at the C. 
burnetii genome itself. As seen in Figure 3.4, the first remarkable feature of this gene 
encoding CBU0388 is its size. At greater than four thousand base pairs in length, this is 
the largest T4SS substrate in the genome. The protein encoded by this gene is 161 kDa 
in size, well over the normal size of other C. burnetii substrates, which averages at only 
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33 kDa. Evolutionary selection would indicate that given its size, CBU0388 must be 




Figure 3.4. Depiction of the C. burnetii genome showing the genomic locus that 






 One idea we wanted to explore further was whether or not CBU0388 was 
conserved throughout strains of C. burnetii. Strains of C. burnetii are classified largely 
by their ability to cause either acute or chronic infections. We compared the genomic 
integrity of the CBU0388 coding region in selected strains to determine whether 
CBU0388 was conserved across broad classes of these strains. The conservation status 
of CBU0388 is shown in Figure 3.5. From the figure, you can clearly see that the full 
length CBU0388 is not present in the Dugway strain, K strain, or G strain, all of which 
do not cause acute disease. In fact, the only strains where CBU0388 was fully intact and 
coding was Nine Mile and Henzerling, another acute disease isolate. In both the Dugway 
and K strains, internal deletions cause frameshift mutations resulting in two separate 
potentially coding regions. In the G strain, bioinformatics analysis predicts the same one 
open reading frame in the acute isolates. Looking at the genomic sequences, however, 
you see there are actually fourteen nucleotide changes that result in multiple frameshifts. 
While there are also numerous changes to the genome in these chronic isolates compared 
to the Nine Mile strain, we hypothesize that CBU0388 may contribute to acute virulence 
since it is only found in full-length form in strains that cause acute disease. The only way 
to test this would be to complement these chronic isolates with a fully coding CBU0388 
to see if there is any effect on their ability to cause acute disease. There are also likely a 
larger number of proteins that contribute to acute virulence than just CBU0388, so you 
may not see any noticeable difference with adding just this one to those strains. This 




Figure 3.5. Conservation of CBU0388 across other C. burnetii strains. Comparison 




Gene expression of CBU0388 is expressed throughout infection. Previous screening 
studies by our lab predicted CBU0388 as potentially regulated by the two component 
system PmrA/B based on upstream sequence homology [30].  A previous paper showed 
the PmrA/B controls gene expression of 43 different genes in L. pneumophila using a 
consensus sequence for binding [79]. That same study also showed the PmrA/B system 
regulated dot/icm genes in C. burnetii. We tested the expression of CBU0388 during 
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axenic growth as well as during infection (see Figure 3.6). CBU0388 appears to be 
stably expressed during infection. The expression level during infection is lower than 
compared to axenic growth. This data was further confirmed by a microarray showing a 
stable expression level of CBU0388 at day 3, 5, 7, 14, and 21 of infection in vero cells 
[62].  
 Given its location in the genome, it was unclear if CBU0388 is the last gene in 
an operon. Since the transposon insertion is at the end of the CBU0388 sequence, there 
is not a high probability of polarity causing the growth phenotype. But if the gene was in 
an operon, it could give us more information about the regulation and importance of the 
gene. We initially tried to identify a promoter upstream of CBU0388 by sequence 
verification and investigate it further through 5’ race analysis. During this process, 
however, a microarray data set was published and showed differential expression of the 
upstream genes rplu, rpmA, and obgE, eliminating the hypothesis that CBU0388 was co-
regulated with these genes [62]. While CBU0388 expression was stable throughout long-
term infection, rplu, rpmA, and obgE expression was higher initially and decreased at 




                      
Figure 3.6. CBU0388 is expressed throughout infection in J774A.1 macrophages. 
Growth curve analysis was done to determine the expression level of CBU0388 both 
during axenic growth in ACCM-2 media and during J774A.1 macrophage infection at 
day 2 and day 4 post-infection. Com1 was used as a control for a gene that is 
constitutively expressed by C. burnetii. Graph shows one representative experiment with 




Nuclear localization and export signals are required for CBU0388 trafficking to the 
host nucleus. Based on our previous observation that CBU0388 is nuclear-localized 
during ectopic expression [31], we hypothesized that CBU0388 uses a NLS to traffic 
into the nucleus of host cells. To test this, we used the pharmacological inhibitor 
Importazole (IPZ), which inhibits the nuclear import receptor Importin B. In CBU0388-
transfected cells treated with Importazole, the protein cannot enter the nucleus and is 
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seen only in the cytoplasm. This suggested that CBU0388 uses the canonical nuclear 
import pathway, which would be dependent on a NLS. We used NLStradamus to 
bioinformatically screen for a canonical nuclear localization signal [64]. Using this 
online prediction algorithm, we identified three potential nuclear localization signals in 
the amino acid sequence of CBU0388 (Figure 3.7). A canonical nuclear localization 
signal is composed of a series of basic amino acids which cause the protein to fold in a 
manner to form a binding pocket for the import adapter protein Importin α. A NLS can 
be either monopartite or bipartite, which contains a linker. To test their contribution to 
nuclear localization, we deleted each predicted NLS and transfected each resulting 
construct into HeLa cells to assess their nuclear translocation. We found that only one of 
the predicted NLSs were fully functional for translocation into the nucleus of the host 
cell (Figure 3.8). Deleting this NLS prevents the protein from entering the nucleus, so 






Figure 3.7. CBU0388’s nuclear localization is dependent on a cannoncial nuclear 
localization signal. Confocal image of HeLa cells transfected with the pEGFP 
CBU0388 ΔNLS plasmid. Shown above is one representative image from at least three 
independent experiments. The NLS amino acid sequence matches a canonical 







Figure 3.8. CBU0388 traffics out of the nucleus with a nuclear export signal. (A) 
Predicted nuclear export signal based compared to a canonical sequence. The portion in 
red indicates the amino acids that match the canonical NES sequence. (B) Representative 
confocal microscopy image of HeLa cells transfected with CBU0388 ΔNES mutant. 




We also identified a nuclear export signal [80] in the sequence for CBU0388 
(Figure 3.8A). Nuclear export signals are usually a stretch of 4-5 hydrophobic amino 
acids, usually leucine, arranged with spacers so they can be recognized by the nuclear 
export receptor Crm1 [81].  The consensus sequence for a typical NES is shown in 
Figure 3.8A. To test the functionality of these sequences in CBU0388 trafficking, we 
transfected a deletion mutant lacking the NES. (Figure 3.8B). In the case of the NES 
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mutant, the protein can enter the nucleus through its NLS, but is unable to be recognized 
by the export receptor Crm1, and is trapped within the nucleus.  These results were also 
confirmed using pharmacological inhibitor Leptomycin B (LepB), which inhibits Crm1-
specific nuclear export [82]. Leptomycin B has been used for over 20 years and 
covalently binds specifically to the Cysteine-529 residue of Crm1 [83]. The high 
specificity of LepB eliminates the possibility of treatment interfering with another 
molecule causing an artifactual result.  
 
CBU0388’s transfection-associated toxicity is dependent on nuclear trafficking. 
Similar to the toxicity seen when CBU0388 is expressed in yeast [84], transient 
transfection in mammalian cells also resulted in toxicity. This phenotype has made 
exploring functionality in these conditions very limited. To understand more about this 
cellular death phenotype, we investigated the type of cell death these cells undergo. As 
shown in Figure 3.9, this toxicity is a result of apoptotic cell death, as determined by 
measuring caspase 3/7 activiation during expression in HeLa cells. At eight hours post 
transfection when no GFP-tagged protein is produced, the caspase activity of both the 
vector and CBU0388 are similar. After twenty-four hours, however, there is a marked 
increase in the amount of caspase activation in the cells transfected with CBU0388. The 
cellular death induced by expression of CBU0388 is similar to treatment with the potent 
apoptosis inducer Staurosporine. Although the activation of Caspase 3/7 is not the only 
indicator of apoptotic death, it was the one we used. Using other readouts for apoptosis 
could further add to the mechanism of this toxicity. Since C. burnetii does not cause 
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apoptotic cell death [58] it can be almost certain that the toxic result is simply an artifact 




                    
 
Figure 3.9 Transfection of CBU0388 causes apoptotic cell death. HeLa cells were 
transfected with indicated plasmids or subjected to Staurosporine treatment and analyzed 




kit, according to 
manufacturer’s protocol.  Graph shows levels of apoptotic cells after eight or twenty-






This cellular toxicity was alleviated, however, when CBU0388 was expressed 
without the NLS or treatment with the pharmacological inhibitor Importazole, which 






Figure 3.10. Toxicity of CBU0388 is dependent on its ability to complete a nuclear 
import-export cycle. (A) HeLa cells were transfected with EGFP N-terminally tagged 
CBU0388, CBU0388 ΔNES, CBU0388 ΔNLS, or vector alone. Cells were treated with 
Importazole for 1 hour before Trypan Blue staining for viability was tested. (B) HeLa 
cells were transfected as in (A) but treated with Leptomycin B (LMB) for 4 hours before 





Conversely, deleting the NES or inhibiting the nuclear export receptor Crm1, prevents 
the toxicity seen with the full-length CBU0388 (Figure 3.10B). Expressing CBU0388 
defective in entering or leaving the nucleus, respectively, does not cause toxicity. 
Therefore, a complete nuclear trafficking appears to be required for full functionality and 
the resulting cellular toxicity. 
CBU0388 has structural similarity to the export receptor Crm1. We used the online 
protein structural analysis software Raptor X (http://raptorx.uchicago.edu/) to predict the 
structure of CBU0388. This predicted a folded protein with structural homology to 
Crm1, the primary nuclear export receptor. 







Figure 3.11. Structural comparison of the predicted folding of CBU0388 and the 
crystal structure of Crm1.  The RaptorX derived protein prediction of CBU0388 (left) 
compared to the known crystal structure of Human CRM1. The structural similarity was 






Here, we present our working model of how the nuclear trafficking of CBU0388 
occurs in a cell infected with C. burnetii (Figure 3.12). Once C. burnetii infects a host 
cell, it secretes CBU0388 into the cytoplasm. Once secreted, the protein then traffics into 
the nucleus via a canonical NLS. Unfortunately, at this point we still do not understand 
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the protein’s nuclear function. CBU0388 is then exported out of the nucleus through 




Figure 3.12. Working model of the trafficking of CBU0388 in host cells. Step I. 
Secreted CBU0388 is imported into the host nucleus through NLS. Step II. CBU0388 
binds to an unknown factor, depicted as Protein X, in the nucleus. Step III. CBU0388 is 
exported along with Protein X resulting in mislocalization of Protein X which results in 
Figure 3.12 cont. toxicity during ectopic expression. Future studies will be to identify 




EMAP analysis of CBU0388 reveals novel pathway targets. To further investigate the 
role of CBU0388 in the host cell, we employed the power of yeast genetics in Epistatic 
Mini-array Profile (EMAP) technology. This technique was developed originally to 
identify shared biological pathways between Saccharomyces cerevisiae and 
Schizosaccharomyces pombe [85]. In a novel screen, EMAP technology was used to 
evaluate genetic interactions between S. cerevisiae mutants and effectors from across 
three different pathogens: C. burnetii, Salmonella enterica serovar Typhimurium, and 
Brucella melitensis [61]. Yeast expressing CBU0388 were crossed with a mutant library 
containing approximately 4600 single deletion mutants and effect on growth was scored 
in a semi-quantitative manner. The resulting data can be sorted into statistically 
significant measure of correlation, represented by a z-score. The results correlate 
strongly with genes involved in spindle pole body positioning, kinetochore, and 
segregation of chromosomes, consistent with a potential modulation of nuclear division 
and the cell cycle. The gene ontology (GO) terms with the highest correlation with 






Figure 3.13. Gene Ontology terms predicted by the EMAP Screen. (A) Enriched GO 
terms for significantly correlating genetic interaction profiles for CBU0388. (B) HeLa 
cells transiently transfected to express GFP-CBU0388, co-stained with Hoechst to 
visualize nuclei. Scale bar, 10μm. Figure adapted from Patrick and Wojcechowskyj, 




C. burnetii does not appear to manipulate cell cycle of the host cell. The EMAP 
results that point to cell cycle manipulation was particularly interesting. C. burnetii 
establishes a long term, sometimes persistently infected cell population. Therefore, it 
would be interesting to see if there was manipulation of the host cell cycle. Early 
experiments looking at cell DNA content as a measure of cell cycle stage have shown 
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that C. burnetii does not cause an interruption in cell cycle [86]. That same study also 
shows that while cell division occurs normally, the CCV is not divided at all. Only one 
of the resulting daughter cells remains infected, while the other becomes uninfected. No 
other studies have been done to test further manipulation of host cell cycle. It could be 
likely that while the global cell cycle stages occur normally, there is a subtle change 
induced by C. burnetii. This, of course, is harder to detect without knowing what 
specific aspects to check. We wanted to see if we could replicate these past cell cycle 
results. We assayed a number of infected cell types (J774A.1, L929 and HeLa cells) with 
similar results across experiments. The flow cytometry graphs (Figure 3.14) show 









Figure 3.14. C. burnetii does not appear to manipulate cell cycle progression. 
Infected L929 cells were stained and subjected to flow cytometry analysis to assess 





Serum starvation synchronization temporarily prevents toxicity induced by 
expression of CBU0388. In order to try to assess the correlation between expression of 
CBU0388 and cell cycle, we decided to synchronize the cells before transfection. While 
this was originally meant to be a tool, the experimental results were unexpected. Serum 
starvation caused all the cells to stall at the G1 phase of mitosis [87]. This treatment, of 
course, has other pleotropic effects. One notable change is that serum starvation changes 
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the transcriptional profile of the cell [88]. When we serum starved the cells before 
transfection, we no longer saw CBU0388-dependent cellular death (Figure 3.15). While 
previous experiments showed almost no cellular viability after only twelve hours of 
transfection, serum starved cells still had normal viability after twenty-four hours.  
 
 
     
Figure 3.15 Serum starvation prevents CBU0388 toxicity in transient transfection. 
HeLa cells were serum starved to synchronize them at G1 phase twelve hours before 
transient transfection. Serum was added back at time of transfection to restart cell cycle. 
Trypan blue staining was done at twenty-four hours and fourty-eight hours post 






The addition of serum at the time of transfection would restart normal cell cycle, 
allowing for normal transcriptional and protein synthesis activity to begin again. The 
synchronized cells were able to express a nuclear-localized CBU0388 without causing 
the typically seen toxicity. Prolonged expression under normal cell cycle caused the 
toxicity to return, however, after forty-eight hours. 
 
Discussion 
 While several nuclear localized C. burnetii T4SS effectors have been identified, 
CBU0388 is the first to be characterized for its role in pathogenesis. This is also the first 
instance where action in the nucleus of the cell can be connected to biogenesis of the 
pathogen-containing vacuole.   
Nucleomodulins and cylomodulins are a broad class of virulence factors that can 
act in the nucleus of the host. While it has not be determined if C. burnetii manipulates 
the mitotic cell cycle during infection, three effectors appear to inhibit exogenously 
stimulated apoptosis to enable host survival and CCV development [57, 89]. Therefore, 
the prediction from the EMAP screen that CBU0388 may act as a nucleocyclin is 
innovative, and if confirmed, could represent a novel mechanism for a secreted nuclear 
effector. 
The biggest shortcoming of this research is the absence of complementation of 
the CBU0388::tn mutant. Major factors including size exclusion and plasmid availability 
complicated the complementation process. Despite multiple efforts, complementation 
attempts failed. In prior work, our laboratory was able to successfully complement a 
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mutation in a different gene in trans [31], but this did not fully work with CBU0388 
(Figure 3.5). This method of complementation depends on cells that are doubly infected 
with both the WT and CBU0388::tn mutant strains at the same time. This is a rare event 
on its own, particularly over a long period of infection. The typical infection rate after a 
week is only about ten percent. This is also a result of cellular growth and only a fraction 
of cell remaining infected. While growth of the mutant could be seen by confocal 
microscopy in rare events by this method (data not shown), there was no significant 
change in the overall population that could be shown by qPCR.  
The only other time our lab has made a successful complementation was with a 
large (10 kbp) vector expressing the protein in the mutant strain [59]. This was still only 
partially effective to restore the growth of the mutant in this case. With the size of the 
vector, we were not able to use this with the large CBU0388 protein. We tried using 
other vector plasmids to deliver the CBU0388 protein into the CBU0388::tn mutant 
without success. We did have the entire genome of the CBU0388::tn mutant sequenced 
(data not shown) which confirmed the transposon insertion in the single CBU0388 ORF. 
Therefore lack of complementation is not due to multiple mutations or mixed culture. 
The latest strategy for complementation tried was using a Tn7 Tet
R
-inducible 
plasmid containing a 3XHA-tagged CBU0388. This vector plasmid was previously used 
for complementation in a C. burnetii mutant and showed a rescue of growth [90]. We 
were able to show induction of the CBU0388 protein in ACCM-2 grown bacterial cells 
(Appendix C) but the kinetics of protein expression in intracellular infection became 
more difficult. We did not see a rescue of growth in any of the induction conditions we 
 
 72 
tried, but protein kinetics could be to blame. Future studies will need to be done to either 
optimize this or create a new complementation strategy.  
Another avenue that still needs to be explored in the mode of action of 
CBU0388. It could be argued that CBU0388 must be important for C. burnetii to 
continually express it as well as maintain such a large ORF in its genome. While the 
EMAP studies point to a possible role in cell cycle, no further experiments have been 
able to confirm this. Protein interaction studies have been difficult with the toxicity that 
comes with CBU0388 expression. We tried a pulldown and mass spectrometry with the 
CBU0388ΔNES and CBU0388ΔNLS mutants expressed in HEK293T cells, but it did 
not result in identification of any interaction partners. There was an overabundance of 
protein interactions, none of which had a high enough mass spectrometry score to merit 
follow-up analysis. One hypothesis could be that CBU0388 does actually interact with 
multiple proteins in the same way as Crm1 binds multiple cargo proteins, but most likely 
our results were due to high background with not enough expression of our tested 













As an obligate intracellular pathogen, C. burnetii must possess multiple 
mechanisms to manipulate the host cell for its own benefit. The host cell nucleus is an 
obvious target for manipulation given its pivotal role as the site of such important 
cellular events such as transcription, DNA replication, and cell cycle.  From the six 
potential type IV secretion-dependent nucleomodulin candidates (Table 4.1), this 
research explored the role of CBU0794 (Cig20) and CBU0388. This project resulted in 
discovery of a novel protein interaction between CBU0794 and the transcriptional 
activator protein TBL1XR1. Although the consequences of this interaction have not yet 
been elucidated, the pivotal role TBL1XR1 plays in multiple pathways could lead to 
very interesting transcriptional consequences. In addition, this project characterized 
CBU0388 as the first nuclear-localized effector in C. burnetii to play a role in 
pathogenesis. This protein, while made a challenge by its size and cellular toxicity, has 
been shown to potentially play an important role in cellular cycle manipulation during 
infection. A model of the role of both of these effectors in C. burnetii infection is 













Figure 4.1. Final representative model of nucleomodulin action in C. burnetii 
infection. Infected cell depicting the large cell variant (LCV) and the small cell variant 
(SCV) of C. burnetii with an active type IV secretion system. In this case, CBU0794 and 
CBU0388 target the host nucleus in order to perform differential roles in transcriptional 






The result that CBU0794 bound to the protein TBL1XR1 brought a plethora of 
potential theories about the consequences of this interaction. The initial idea was that 
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CBU0794 bound to TBL1XR1 in order to prevent binding of the SMRT/NCoR to DNA, 
thus allowing transcription to occur. This was shown not to be the case, as the RNA-seq 
failed to show any activation of transcription in the presence of CBU0794 (Figure 2.10). 
It makes sense that C. burnetii would not want to activate overall cellular transcription in 
such a non-specific way. Since CBU0794 is present throughout infection, this must also 
be a long-term transcriptional modulation. Instead, some sort of controlled differential 
transcription would be more beneficial to the bacteria. Alternately, an upstream signal 
may have been necessary to cause the transcriptional response to be present.  
 Another hypothesis could be that CBU0794 was binding TBL1XR1 to cause 
degradation of the protein or the complex. This could be through some post-translational 
modification that would mark it for degradation. This also seemed to be ruled out as a 
hypothesis since protein levels of TBL1XR1 as well as SMRT and NCoR all appear to 
be the same both in the presence or absence of CBU0794 (Figure 2.8). Similarly, if 
CBU0794 were just sequestering TBL1XR1 from the SMRT/NCoR complex, the cell 
could compensate by increasing protein levels of TBL1XR1. This does not happen. You 
would also potentially see increased transcription in the case, but we fail to see that.   
 Another major hypothesis to consider is the involvement of CBU0794 in the 
Wnt/β-catenin pathway. In normal cells, the presence of the signaling molecule β-catenin 
causes TBL1XR1 to become SUMOylated, causing it to leave the SMRT/NCoR and 
form a new complex with β-catenin that directs transcription of Wnt-regulated genes. 
The presence of a higher molecular weight subspecies of TBL1XR1 in the presence of 
CBU0794 seems to support this theory (Figure 2.9). Of course, further confirmation of 
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this still needs to be done to determine if this is indeed a result of SUMOylation or some 




Figure 4.2. Hypothetical representation of the effect CBU0794 expression in the 
host cell. (A) An image representative of a normal cell with TBL1XR1 bound to the 
NCoR/SMRT complex as a transcriptional repressor. (B) Our hypothesis depicting 
Figure 4.2 cont. CBU0794 bound to a SUMOylated TBL1XR1, which redirects it from 







In the CBU0794 pulldown, we only found TBL1XR1 alone, not other members 
of the SMRT/NCoR-HDAC3 complex. It would be safe to say then that CBU0794 
interacts with TBL1XR1 alone, not in the context of a larger protein complex. Of course, 
the complex may not have been pulled down in the experiment due to the large size of 
the complex, protein degradation, or protein instability. A representation of our 
hypothesis of CBY0794 action is presented in Figure 4.2.  
The obvious caveat to all of this data is that it was not done in the context of an 
infected cell. We do not have the ability to create a CBU0794 mutant in the context of 
this project. The addition of a deletion mutant of this protein in the future will provide 
further evidence of the important role of CBU0794 in C. burnetii pathogenesis. Another 
important experiment would be to confirm localization of CBU0794 to the nucleus 
during infection. This has proven to be a tricky experiment but could lend more 
information about the temporal and spatial requirements for CBU0794 during infection. 
This experiment could be done by microscopy or western blot using a tagged version of 
CBU0794 in C. burnetii.  
 
CBU0388 
CBU0388 has been a challenge to understand. Its remarkable size of a 161kDa 
protein makes it the largest effector protein in C. burnetii. In fact, its size is even more 
significant if you consider that C. burnetii has a relatively small genome in total. The 
coding region of CBU0388 takes up 0.2% of genetic coding space in the genome. 
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Despite evolutionary pressure over time, C. burnetii has retained this large protein as a 
secreted effector in acute isolates, so it can be inferred that it must be required.  
We explored the requirement of this protein in a virulent SCID mouse model and 
multiple tissue culture cell lines. While complementation has been elusive, I have no 
doubt that the mutant phenotype is solely a result of the loss of CBU0388 during 
infection. The CBU0388::tn mutant was unable to grow in any cell line, whether an 
epithelial cell, macrophage cell line or primary macrophage. C. burnetii needs CBU0388 
in a fundamental way, not specific to immune evasion or cell-specific recognition.  
 An interesting finding was the identification of functional nuclear trafficking 
domains that CBU0388 uses to both enter and leave the nucleus of the host cell. This in 
and out style nuclear trafficking is unique to this effector. While nuclear localization 
signals are common among nuclear effectors in bacteria, a nuclear export signal is not, 
although multiple reports of nucleocytoplasmic trafficking by viral proteins have been 
documented [91]. C. burnetii has evolved a unique effector protein that traffics similar to 
a eukaryotic protein. In fact, it seems to have more in common with a eukaryotic protein 
than a bacterial effector. My initial hypothesis was that CBU0388 was entering the 
nucleus to find a binding partner, termed Protein X. Once bound to its target, it could 
potentially mis-localize this Protein X into the cytoplasm so that the function of Protein 
X cannot be performed. In pulldown experiments, however, Protein X was unable to be 
identified using GFP-tagged NLS and NES mutants. This lack of result could be due to 
the methodology and transfection not being sufficient for detection by pulldown. It could 
also be that my hypothesis about Protein X was not correct.  
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Another hypothesis is that CBU0388 may not bind Protein X, but rather modify 
it in some way to prevent or enhance functionality. Assuming the identity of Protein X 
belongs to a protein important for allowing C. burnetii to grow in any cell type, it would 
be important to modulate its function for the benefit of the bacteria. This could be 
accomplished by activating Protein X through some modification such as 
phosphorylation or acetylation. Instead, CBU0388 could recruit E3 ligases to 
ubiquitinate Protein X for destruction but it does not contain any ligase domains. This 
hypothesis wouldn’t explain the movement out of the nucleus, however, as this 
modification could easily occur in the nucleus.  
Alternatively, CBU0388’s nuclear movement may not result in a particular 
protein binding. That being, it may bind a whole host of proteins. Given its structural 
homology to the nuclear export receptor Crm1, it may be acting as a mimic to co-opt all 
nuclear export. In this case, CBU0388 could act as a shuttling protein to remove multiple 
components from the nucleus. This could be a way for C. burnetii to deliver nuclear 
components directly to the cytoplasm or CCV. Since we don’t know most of the 
requirements for a stable CCV, it would be hard to determine if this was the case. We do 
not actually know if CBU0388 accumulates in the cytoplasm of an infected cell or if it 
interacts directly with the CCV. Localization of CBU0388 in an infected cell would 
answer this question. This hypothesis of CBU0388 acting as a bacterial-specific shuttle 
would most likely negate any specificity CBU0388 may have in its nuclear interactions.  
Likely, one or more of these hypotheses could be true. Given its large size, 
CBU0388 may perform multiple actions during infection, including acting as a nuclear 
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shuttle. We can ask ourselves: what nuclear proteins would be worth employing such an 
effector as CBU0388 to modulate? The answer is not a simple one. Nor is it an obvious 
one.  
Our EMAP yeast screen pointed towards a potential role of CBU0388 in cell 
cycle control. Despite my results and long-standing consensus that C. burnetii does not 
disrupt cell cycle, this does not rule out this hypothesis. Besides overt disruption of cell 
cycle, CBU0388 could play a role in modulating a key regulator for another purpose. 
The EMAP screen presents a profile matching profiles of yeast that express your effector 
protein with a profile of yeast genetic mutant. CBU0388 had the strongest data of all the 
effectors we tested, matching it to the nuclear division or cell cycle pathways. The fact 
that C. burnetii does not effect cell cycle provides further information to this finding and 
could point to a role in cellular division.  
A unique feature of C. burnetii is that during cellular division, the CCV only 
goes to one single daughter cell instead of also splitting into two. After mitosis occurs, 
only one of the two resulting daughter cells stays infected while the other is uninfected 
[86]. This seems like a weird phenomenon if the bacteria want to maintain a persistently 
infected cell population. It could simply be a way to maintain its stealth pathogen status. 
Since we do not know how C. burnetii escapes a cell and spreads to others, answering 
these questions become difficult. One confounding factor is the requirement for 
CBU0388 in order to establish a replicative niche. There is no known data about the 
requirements for C. burnetii making a functional CCV. It’s unclear what host nuclear 
factors could be crucial to establishing a CCV and initiating bacterial replication.  
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 This is really the first step to understanding the role of CBU0388 in C. burnetii. 
We really don’t know the consequences of CBU0388 action during infection, despite a 
clue that it is involved in chromatin segregation and division. Further studies should 
focus on establishing the precise protein interactions of CBU0388. Does it interact with 
a single protein partner or multiple? Does it bind DNA or RNA? Why does C. burnetii 
need such a large effector protein to traffic in and out of the nucleus?  
Final Conclusions 
 Coxiella burnetii is an obligate intracellular pathogen that has developed a 
unique repertoire of type IV secreted effectors to promote its survival, vacuole 
formation, and intracellular replication. Over 100 secreted effectors have been identified 
through several screens, most of which lack a defined function. Of these, six have been 
described as having nuclear localization during ectopic expression in tissue culture cells. 
Two of these effectors, CBU0794 and CBU0388, have been highlighted in this study.  
  The nucleus has long been perceived as the brain of the cell, giving instructions 
for multiple cellular processes for the benefit of the cell. Modern research has further 
focused on the importance of bacterial manipulation of the nucleus to also allow bacteria 
to benefit. Bacteria have employed a class of secreted effectors, termed Nucelomodulins, 
to carry out targeted roles in manipulating the brain of the cell for survival of bacteria 
within host cells. While intracellular dynamics are complex, relying on multiple 
coordinating pathways, bacteria have evolved multiple strategies to co-opt these 
pathways. The effectors described here are only the first step in understanding the action 
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of nucleomodulins in C. burnetii. Future studies could reveal just how powerful and far-
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One way to understand the effect of CBU0794 on TBL1XR1 was to observe the 








Figure A1. Expression of TBL1XR1 related genes in bone marrow-derived 
macrophages. RNA was isolated from infected BMDMs 24 hours after infection. qRT-
PCR was done for specific immune genes as shown. The graphs presented are one 





Figure A2. Transfection efficiency of constructs for RNA-seq. In order to be assured 
of both adequate and similar transfection rates for comparison during the RNA-seq, we 
compared transfection efficiency from all three replicates. The CBU0794 construct had 
more consistent transfection rates, but it was significantly higher than the 










Figure A3. Additional RNA-seq analysis figures. The first three panels are volcano 
plots showing each individually expressed transcript. The last panel is a principal 








Figure A4. Up-regulated genes specific to CBU0794 expression.  
 
 











To ensure the growth defect seen in the CBU0388::tn mutant was not a result of fitness 









Figure B.1 Growth defect of CBU0388::tn transposon mutant is not due to fitness 
of bacterial strain. qRT-PCR was done on each strain grown in ACCM-2 for up to 7 












One of the hypotheses that developed from CBU0388’s structural homology to Crm1 
was potential disregulation of the molecule RAN, which acts as the key energy source 
for nuclear import and export.  We tried several ways to test this, but ultimately 
concluded that while it does appear that RAN is somehow manipulated during infection, 




Figure C.1 RAN Expression during transient transfection of CBU0388. HeLa cells 
were transfected with either pEGFP-C1 vector of pEGFP-C1 CBU0388. Twelve hours 
post-transfections, cells were fixed and stained for RAN. Merged images are shown 
above. The amount of RAN present in cells transfected with CBU0388 appears to be 
much lower, but this may be an artifact of high cellular toxicity in these cells. Cell nuclei 







Figure C.2 RAN Expression in Infected HeLa cells. HeLa cells were infected with 
each indicated strain normally and fixed at four days post infection. Staurosporine 
treatment is used as an additional comparision. Merged images are shown above. Cell 
nuclei are stain blue with Hoescht. RAN is stained with red. LAMP1 is used as a marker 







Figure C.3 Gene Expression of RAN during infection. HeLa cells were infected 
normally and RNA isolated at both four or seven days post-infection. Quantitative PCR 
was done to test for levels of RAN in each sample. Data is from a single experiment with 










Figure C.4 RAN protein levels are modulated during infection independently from 
Type IV Secretion. Western blot of infected HeLa cells were done at either four or 
seven days post-infection. Samples were blotted for RAN and Actin as a loading control. 
Graph is quantitative ratio from three separate experiments. While the proteins levels of 
RAN appear to be significantly lower in infected cells than uninfected, this does not 


























Figure C.5 Knockdown of RAN during infection in HeLa cells.  (A) Transient 
knockdown of RAN successfully diminished the expression of RAN in HeLa cells 
compared to the scrambled DNA control. (B) HeLa cells were infected with wild-type C. 
burnetti. At twenty-four hours post-infection, cells were treated with the siRNA to 
knockdown the expression of RAN. At days 3 and 5 post-infection, cells were analyzed 
for replication. At day 5-post infection, there appeared to be a marked decrease in the 
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replication of C. burnetii compared to the controls. Graph shows the means from one 













































The current and most effective strategy for complementation of the CBU0388::tn mutant 
so far has been the use of an inducible plasmid, shown in Figure C.1. This plasmid 
contains an anhydrotetracycline-inducible promoter, 4xHA tag, a Kanamycin and 
Ampicillin resistance casette, and a Tn7 transposon. CBU0388 was able to be 
successfully cloned into this plasmid and transformed into C. burnetii successfully along 
with the helper Tn2 plasmid, which contains the transposase. PCR of multiple C. 
burnetii clones have shown the insertion of the Kanamycin resistance cassette in the 
genome, as seen in Figure C.2. Induction of the 4xHA-tagged CBU0388 appears to be 
somewhat successful. As seen in Figure C.3 when probed for the HA tag, you can detect 
tagged CBU0388. Unfortunately, the product appears to be C-terminally cleaved as you 








Figure D.1. Plasmid delivery vector for Tn7 Tet
R
-Inducible 3xHA-tagged 
CBU0388. Plasmid map made with Serial Cloner showing antibiotic selection, marker, 






Figure D.2 PCR check for Kanamycin in multiple C. burnetii clones. Multiple C. 
burnetii clones transformed with CBU0388-HA plasmid or CBU0388ΔNES-HA plasmid 
were checked for Kanamycin insert in genomic DNA. Positive control is Kanamycin in 










Figure D.3. Induction of CBU0388 in ACCM-2 grown bacteria. Western blot of 
induced expression of 3xHA-tagged CBU0388 in the CBU0388::tn mutant. Multiple 
bands present was typical of all experiments most likely due to degradation by C-











Protein pulldown of CBU0388 ΔNLS and CBU0388 ΔNES compared to pEGFP-C1 
vector in 293T cells failed to produce a reasonable list of unique protein interactions. 
This could be due to CBU0388 interacting with a plethora of proteins in a non-specific 
way. Most likely, though, we did not achieve a good expression level of CBU0388 
ΔNLS and CBU0388 ΔNES to produce a specific result.  
 
Deletion E & L 
GRP75; Glucose related protein 75 
RSSA 40S ribosomal protein 
PHB2 Prohibitin  
SERA; D-3-phosphoglycerate dehydrogenase aka PHGDH  
LDHB; lactate dehydrogenase B chain  
RU2A; U2 small nuclear ribonucleoprotein A  
RA1L2;  nuclear ribonuceloprotein A1  
PCBP2; Poly (r:C) binding protein 2 
TCPQ; T-complex protein 1 subunit theta  
KPYM; pyruvate kinase 
ALDOA; Fructose-bisphosphate aldolase  
 
 112 
LDHA; lactate dehydrogenase chain A  
CAZA1/ F-actin capping protein subunit alpha  
 
Figure E.1. Protein results seen in both the CBU0388 ΔNES and CBU0388 ΔNLS 




Deletion E only 
Parp1  
FUB2; far upstream binding element  
RL40; 60S ubiquitin ribosomal L40 
TCPB; T-complex protein 1 subunit  
CALX; Calnexin  
C1QBP; complement component 1 Q subcompotent binding protein  
 









A previous paper [84] concluded that CBU0388 played a role in preventing activation of 
the Cell wall integrity (CWI) MAPK pathway. This paper used yeast to screen a number 
of C. burnetii effector proteins. CBU0388 is not just toxic when expressed in 
mammalian cells, but also yeast. This paper utilized this fact and used specific deletion 
mutants in the CWI pathway to compare the toxicity of CBU0388. They found that 
deletion in bck1 and mpk1, equivalent to map3k and mapk respectively, resulted in 
alleviating the toxicity caused by CBU0388. With this implication that CBU0388 
prevents MAPK pathway activation, we tried to confirm this in mammalian cells. The 
difficulty was that the CWI pathway is highly conserved in fungal cells, but doesn’t have 
a direct equivalent in mammalian cells. We therefore tested multiple MAPK pathway 
inhibitors in their ability of alleviate toxicity of transfected CBU0388 in HeLa cells. We 
used four different inhibitors: U0126 (ERK1/2 inhibitor), SB203580 (p38 inhibitor), 
SP600125 (JNK inhibitor), and Dexamethasone (pan-MAPK inhibitor).  Results shown 
in Figure F.1 show that we could not find any inhibitor that prevented the cellular 
toxicity caused by CBU0388. We therefore, could not tie CBU0388 to the mammalian 
MAPK pathway. Of course, the MAPK pathway is extremely involved with a number of 
other molecules playing a role in signaling. Therefore, this experiment does not 
completely rule out the involvement of CBU0388 in modulating some form of the 




Figure F.1. MAPK inhibitors don’t rescue cellular toxicity seen by CBU0388 in 
HeLa cells. (A) Schematic depicting the MAPK branches and targets of each 
pharmacological inhibitor used in this experiment. (B) Trypan blue staining to assess 
cellular toxicity of cells transfected with CBU0388 with or without pharmacological 
inhibitors. Staurosporine is used as a positive control for inducing toxicity. Graph shows 
the average +/- SD of three independent experiments. Statistical analysis revealed results 
were non-significant compared to CBU0388 transfection alone.   
